In United States, dermatomyositis is managed by rheumatologists. Dermatomyositis is a rare autoimmune myopathy with characteristic cutaneous features, affecting roughly 1-10 new cases per million adults per year. It is defined by symmetric proximal muscle weakness developing over weeks to months alongside pathognomonic skin signs — heliotrope rash on the upper eyelids and Gottron papules over the knuckles, elbows, and knees.
Dermatomyositis (ICD-10: M33.1, M33.0 for juvenile) is an immune-mediated inflammatory myopathy characterised by symmetric proximal muscle weakness and pathognomonic skin findings. The pathology centres on a perifascicular atrophy pattern with complement-mediated capillary injury and a Type 1 interferon signature; the disease is now understood as a humoral and interferon-driven vasculopathy rather than a purely T-cell-mediated myositis. The 2017 EULAR/ACR classification criteria require characteristic skin findings (heliotrope, Gottron) or muscle weakness pattern, supported by elevated muscle enzymes (creatine kinase, aldolase), abnormal electromyography, MRI muscle oedema, and biopsy showing perifascicular atrophy. Myositis-specific autoantibodies define clinically meaningful subsets: anti-Mi-2 (classic skin and muscle, good response), anti-MDA5 (clinically amyopathic with rapidly progressive interstitial lung disease, especially in East Asians), anti-TIF1γ and anti-NXP2 (strong cancer association in adults), anti-SAE (rapid skin onset with subsequent muscle disease), and anti-synthetase antibodies including Jo-1 (interstitial lung disease, mechanic's hands, Raynaud).
The key symptoms of Dermatomyositis are: Symmetric proximal muscle weakness developing over weeks to months — difficulty rising from chairs, climbing stairs, lifting arms overhead, or washing hair., Heliotrope rash: violaceous discolouration of the upper eyelids with or without periorbital oedema, often the first cutaneous finding., Gottron papules: pink-purple papules over the dorsal metacarpophalangeal and interphalangeal joints; sometimes also elbows, knees, or medial malleoli., Photodistributed violaceous erythema on the upper chest (V-sign), upper back and shoulders (shawl sign), and lateral thighs (holster sign)., Periungual erythema, dilated capillaries on capillaroscopy, and ragged cuticles with painful infarcts., Mechanic's hands — fissured, hyperkeratotic, dry skin on the lateral fingers and palms — in the antisynthetase syndrome., Dysphagia with choking or nasal regurgitation from pharyngeal and upper oesophageal striated muscle involvement..
Diagnosis follows the 2017 EULAR/ACR classification criteria, which use a probability score based on age at onset, pattern of muscle weakness, cutaneous features, laboratory findings, and (where available) muscle biopsy. The minimum workup includes serum creatine kinase, aldolase, transaminases (often raised from muscle), lactate dehydrogenase, full blood count, urinalysis, antinuclear antibody, and myositis-specific antibody panel covering Mi-2, MDA5, TIF1γ, NXP2, SAE, and the synthetases (Jo-1 plus less common targets). Electromyography typically shows short-duration low-amplitude motor unit potentials with fibrillations and complex repetitive discharges; MRI of the thighs demonstrates muscle oedema (STIR hyperintensity) and atrophy and guides biopsy site. Muscle biopsy showing perifascicular atrophy, perivascular CD4 and B-cell infiltrates, MHC class I upregulation, and capillary depletion is highly supportive. High-resolution CT chest, pulmonary function tests with DLCO, and echocardiography assess interstitial lung disease and cardiac involvement. Video-fluoroscopic swallow study identifies pharyngeal and oesophageal dysphagia. All adults must undergo malignancy screening — chest, abdominal, and pelvic CT, mammography, gynaecological examination, faecal occult blood or colonoscopy if indicated by age, and tumour markers (CA-125 in women, PSA in men) — repeated annually for 3 years from diagnosis, given the 15-25% cancer association.
Outlook has improved substantially over the past three decades. With modern combination therapy, 5-year survival is now 80-90% in adult dermatomyositis without ILD or cancer, and 95% in juvenile disease. The main predictors of poor outcome are anti-MDA5 antibody with rapidly progressive interstitial lung disease (1-year mortality up to 40-60% in untreated East Asian cohorts), associated malignancy, severe dysphagia with aspiration, and cardiac involvement. Anti-TIF1γ-positive adult patients have the highest cancer risk (around 50% within 3 years). Sustained remission off all immunosuppression is achieved by a minority; most patients require long-term low-dose steroids or steroid-sparing therapy. Calcinosis develops in 30-70% of juvenile cases and 10-20% of adults and is difficult to reverse. Treatment of an associated cancer often substantially improves dermatomyositis; persistent disease after cancer therapy implies a separate non-paraneoplastic course.
Suspected dermatomyositis requires rheumatology referral for myositis-specific antibody testing, EMG, MRI, biopsy, and ILD workup. Anti-MDA5 patients with rapidly progressive lung disease should be managed jointly with respiratory medicine in a tertiary centre. Cancer screening should be coordinated with oncology and primary care. Juvenile cases need paediatric rheumatology with calcinosis and growth surveillance.
Find specialists →Muscle enzymes typically fall within 4-8 weeks of induction. Strength recovery lags enzyme normalisation by 6-12 weeks. Cutaneous improvement is often slower than muscle improvement. Maximum response usually occurs by 6-12 months. Steroid tapering targets prednisolone 5-10 mg/day by 6-12 months. Long-term maintenance on methotrexate or mycophenolate is typical for 2-5 years.
Begin gentle range-of-motion exercises and light isometric work during the acute inflammatory phase under physiotherapy guidance — bed rest worsens deconditioning. Once muscle enzymes normalise, progress to graded resistance training and aerobic exercise (3-5 sessions per week, 30-45 minutes). Severe weakness or interstitial lung disease may need pulmonary rehabilitation. Avoid sun exposure during outdoor exercise.
Choose a rheumatology centre with access to the full myositis antibody panel, muscle biopsy and pathology expertise, and a multidisciplinary ILD service. Ask about IVIG, rituximab, and JAK inhibitor availability. Confirm a structured cancer screening pathway for adult patients.
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026
Ranked by patient outcomes and specialized experience.
Specialists who treat Dermatomyositis. Get expert guidance and personalized care.